The combination of a small-molecule inhibitor of the PI3K/AKT pathway (Temsirolimus) with trabectedin (an antineoplastic agent) has shown efficacy in a cohort of patients with ovarian clear cell carcinomas harboring the ARID1A mutation [40,41,42]. Here, PIK3CA is linked to ovarian clear cell cancer.